Japan's former Emperor Akihito hospitalized to get new treatment for heart condition
Akihito was diagnosed in May with myocardial ischemia, an asymptomatic heart condition of reduced blood flow from the coronary arteries to the heart muscle. He has since been on medication to improve blood flow to his heart while avoiding excessive exercise and reducing liquid intake.
Akihito abdicated in 2019, handing over the Chrysanthemum Throne to his son, current Emperor Naruhito and now holds the title of Emperor Emeritus.
After two months on the medication, doctors found little improvement in Akinito's condition and decided to give him an additional treatment to alleviate the burden on his heart, the Imperial Household Agency said.
Monday's hospitalization was to carefully determine the right dose of the new medication to avoid side effects, while monitoring his heart by electrocardiogram and other examination, the IHA said.
In 2012, Akihito underwent a coronary artery bypass surgery. Three years ago, he was diagnosed with right heart failure caused by tricuspid valve insufficiency.
Akihito was seen in the back seat of a palace car, wearing a white surgical mask and accompanied by his wife, Empress Emerita Michiko, as he was taken to the hospital.
Palace officials said they couldn't say how long Akihito would have to be hospitalized.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
What Factors Influence a Patient's Success on GLP-1s?
Longer treatment duration, not having diabetes, and using semaglutide were among the factors associated with better weight reduction over 12 months among patients taking GLP-1 receptor agonists (RA), a cohort study suggested. 'Treatment responses differ among patients receiving GLP-1 RAs, and the weight fluctuations and associated factors following [their] use have not been adequately characterized,' Linong Ji, MD, of Peking University People's Hospital in Beijing, China, told Medscape Medical News . The findings, published online in Diabetes, Obesity and Metabolism , 'may provide novel insights into weight fluctuations after GLP-1 RA treatment in a real-world setting,' he said, potentially advancing the development of individualized strategies for patients. 'Corroborates Other Studies' Researchers conducted a real-world, single-center, retrospective study of 679 patients with overweight or obesity who initiated GLP-1 RA treatment between November 2022 and October 2024. At baseline, participants had a mean age of 37 years, and 31% were men. The mean BMI was 33.4, and 21% were diagnosed with diabetes. The GLP-1 RAs used in the study included semaglutide (Ozempic), liraglutide (Victoza), lixisenatide (Lyxumia), beinaglutide (Yishengtai), exenatide (Bydureon), dulaglutide (Trulicity), and PEG-loxenatide (Fulaimei). All were available for participants with both type 2 diabetes (T2D) and overweight/obesity. For participants with overweight/obesity but without T2D, only Ozempic or Victoza were routinely prescribed, with off-label documentation and informed consent. Weight measurements were collected during in-person clinic visits, and weight fluctuation curves were stratified into three phenotypes — Successful Weight Reduction, Remaining Stable, and Weight Regain. Subsequently, the association between potential influencing factors and weight fluctuations was estimated by univariate and multivariate logistic regression. Subgroup analyses were performed in participants with obesity, prediabetes, and in those using liraglutide or semaglutide. Researchers found significant differences in the duration of GLP-1 RA treatment across groups at the 3-, 6-, and 12-month follow-ups. The Successful Weight Reduction group had a significantly longer duration of GLP-1 RA treatment than the Remaining Stable group and a longer duration at both the 6- and 12-month follow-ups than the Weight Regain group. Diabetes status also showed group differences. At both the 3- and 6-month follow-ups, the proportion of patients with T2D in the Successful Weight Reduction group was lower than in the Remaining Stable group. Types of GLP-1 RAs varied between groups, and at the 3- and 6-month follow-ups, the Successful Weight Reduction group was more likely to have initiated treatment with semaglutide than the Remaining Stable group. Patients with a longer duration of GLP-1 RA treatment (odds ratio [OR], 1.014) and higher Homeostasis Model Assessment of Beta-Cell Function levels (OR, 4.912) were more likely to achieve successful weight reduction at the 12-month follow-up. Nondiabetic status (OR, 2.176) and using semaglutide (OR, 2.138) were associated with successful weight reduction at the 6-month follow-up. In addition, a higher percentage of body fat in both men (OR, 3.990) and women (OR, 2.266) was associated with successful weight reduction. The weight regain group had a higher baseline estimated glomerular filtration rate than the Successful Weight Reduction group and the Remaining Stable group at 3-month follow-up, especially among participants with prediabetes. Ji said this finding surprised him. Patients with obesity often exhibit a state of renal hyperfiltration, characterized by elevated renal plasma flow and glomerular filtration rate, which can be reversed by weight reduction. The finding suggests that patients with renal hyperfiltration might be less likely to experience durable weight reduction, Ji said. 'However, few studies have revealed similar observations. Therefore, further validations and investigations are still needed for this finding.' Furthermore, the team found a positive nonlinear association of serum creatinine with successful weight reduction at 12 months — a finding that will also require additional investigations to examine the mechanism underlying the association. Overall, Ji concluded that while longer duration of GLP-1 RA treatment using semaglutide, nondiabetic status, and higher percentage of body fat might be associated with better weight reduction, 'basal metabolic rate, skeletal muscle mass, muscle mass of the abdomen and limbs, and serum creatinine were nonlinearly associated with the probability of successful weight reduction.' Randy Seeley, MD, Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences at the University of Michigan School of Medicine, Ann Arbor, Michigan, and director of the National Institutes of Health-funded Michigan Nutrition Obesity Research Center, told Medscape Medical News , 'The main results of the study agree with what the field has already seen. Although it is a relatively small study, it corroborates other larger studies,' said Seeley, who was not involved in the study. This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project. Ji reported receiving fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly and Company, Roche, Sanofi-Aventis, and Takeda. Seeley reported that his lab has worked with both Novo and Lilly (and others trying to enter the space), and he has also served as a paid consultant for both of those companies (and others trying to enter the space).
Medscape
3 hours ago
- Medscape
Chronic Conditions Raise Risk for RSV Hospitalizations
TOPLINE: Children with chronic medical conditions (CMCs) had higher rates of respiratory syncytial virus (RSV)-related hospitalization than healthy children during their first two RSV seasons, with a sustained elevated risk in the second year. METHODOLOGY: Researchers conducted a retrospective population-based cohort study to identify children with CMCs who were at a higher risk for RSV-related hospitalizations during their first and second RSV seasons. They enrolled 431,937 children (51.4% boys) born in British Columbia, Canada, between April 2013 and March 2023, with or without a CMC, identified through the provincial health registry. The children were followed up until the day before their third RSV season or April 1, 2024, whichever came early. They compared RSV-related hospitalizations between 25,452 children diagnosed with at least one of 1116 distinct CMCs within their first 2 years of life and those without CMCs. The primary outcome was hospitalization due to RSV-related lower respiratory tract infection. Secondary outcomes included pediatric ICU admissions, hospital length of stay, and use of invasive mechanical ventilation. TAKEAWAY: In the first RSV season, the hospitalization rate per 1000 person-years was 15.9 (95% CI, 14.2-17.6) for children with CMCs and 8.0 (95% CI, 7.7-8.3) for those without CMCs. In the second season, the rate was 7.8 (95% CI, 6.7-8.8) for those with CMCs and 2.2 (95% CI, 2.1-2.3) without CMCs. Children with CMCs had longer hospital and pediatric ICU stays and required mechanical ventilation more frequently during their first two RSV seasons than healthy children. RSV-related hospitalization rates in the second season among children with CMCs involving the respiratory, cardiovascular, or gastrointestinal systems were twofold higher than the overall hospitalization rate in the first season. Moreover, children with Down syndrome or those born at less than 28 weeks of gestation had fivefold higher RSV-related hospitalization rates in the second season than all children in the first season. IN PRACTICE: 'Understanding the regional burden of RSV disease is critical to inform local RSV immunization guidelines. In regions with high IRs [incidence rates], a universal RSV prophylaxis program may be warranted. However, in jurisdictions with a lower burden of disease, targeted programs for children at high risk in their second RSV season may be more cost-effective,' the authors wrote. SOURCE: The study was led by Marina Viñeta Paramo, MBBS, Department of Pediatrics, University of British Columbia in Vancouver, British Columbia, Canada. It was published online on July 8, 2025, in JAMA Network Open. LIMITATIONS: The use of retrospective health administrative data may have introduced biases due to coding variability and misclassification of RSV cases. The analysis did not account for the timing of CMC diagnoses or treatments received. The frequent co-occurrence of extreme prematurity in children with CMCs limited the ability to separate their independent effects. Additionally, the database excluded children not registered for provincial health insurance at birth, potentially omitting vulnerable populations. DISCLOSURES: This study was supported by financial aid to three authors, including funding from the British Columbia Children's Hospital Foundation. Two authors received financial support or a scholar award from Michael Smith Health Research BC. One author received grants from Merck, GlaxoSmithKline, Sanofi Pasteur, Moderna, and Pfizer. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
3 hours ago
- Medscape
DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo
The FDA rejected a supplemental Biologics License Application (sBLA) for glofitamab-gxbm (Columvi, Genentech) in combination with gemcitabine and oxaliplatin for the second-line treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who are not candidates for autologous stem cell transplant. A complete response letter from the FDA stated that Genentech's phase 3 STARGLO trial did not provide sufficient evidence to support the proposed second-line DLBCL indication for the T cell engaging bispecific antibody in the US, according to a Genentech statement. However, a conditional FDA approval in the third-line or greater setting remains in place. FDA's decision regarding second-line glofitamab aligns with an advisory committee vote in May, which cited a lack of US patient representation in the trial. The Oncologic Drugs Advisory Committee (ODAC) voted 8-1 against recommending approval, as reported by Medscape Medical News . The FDA asked for ODAC review over concerns that nearly half of the STARGLO participants were from Korea, Taiwan, and China, with most of the remaining participants coming from Europe and Australia. Only 25 US patients were included. Outcomes among Asian vs non-Asian patients differed, with a strong trend toward worse overall survival (OS), rates in White patients and patients from Europe and the US, despite a strong overall 0.59 hazard ratio for OS. Similar trends were observed for progression-free survival and complete response rates. At the time, the FDA said the low US enrollment 'limits the agency's ability to assess the applicability of the study results to a US patient population,' and cited additional concerns regarding comparator drugs used in the trial, according to meeting documents. 'While we are disappointed with this outcome, we remain confident in the data supporting the value of Columvi for US patients who have relapsed following initial treatment, and its key role as monotherapy in the third-line setting,' Genentech's Chief Medical Officer and head of Global Product Developments, Levi Garraway, MD, PhD, said in the company statement regarding the sBLA rejection. 'We are committed to bringing Columvi to more people living with lymphoma and are actively exploring its potential in additional treatment settings, including as frontline therapy.' 'For patients with this aggressive form of lymphoma, effective treatment after relapse is paramount,' added Jeremy Abramson, MD, the principle STARGLO investigator and director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, Boston. Abramson stressed that in the STARGLO trial, the glofitamab combination therapy improved OS, which 'could have a positive impact for patients earlier in their treatment journey.' The regimen is currently approved for this indication in more than 35 countries. It is approved in more than 60 countries for third-line or greater treatment of DLBCL, including in the US where the FDA granted accelerated approval in 2023. STARGLO was also intended as a post-marketing confirmatory study to support conversion of the accelerated approval to full approval, Genentech noted. Results were published in 2024 in The Lancet, and 2-year follow-up data showing sustained overall improvements in the primary and secondary endpoints were presented at 2025 American Society of Clinical Oncology Meeting. Genentech said the regimen is currently being investigated in combination with other agents as a first-line treatment for DLBCL in the phase 3 SKYGLO study.
